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Cyclin E, together with cyclin-depen-
dent kinase 2 (CDK2), functions as a
gatekeeper to promote G1/S transitions
and the initiation of DNA replication. In
normal cells, cyclin E–associated kinase
activity is exquisitely regulated, with ac-
tivity being limited to a brief time interval
between late G1 and early S phase.
Human cancers frequently exhibit dereg-
ulated cyclin E–associated kinase activity
resulting from overexpression of cyclin E
and loss of cyclin-dependent kinase inhi-
bition (via p53 mutations) promoting
genetic instability and cell proliferation
[1]. Increased levels of cyclin E correlate
with tumorigenesis and are a poor prog-
nostic indicator independent of prolifera-
tion rate, suggesting that cyclin E’s role in
tumorigenesis is not limited to promoting
increased cell proliferation [2,3]. By elim-
inating regulatory constraints using p53
null cells, we and others have shown that
overexpression or endogenous expression
of stabilizing mutant forms of cyclin E can
lead to hyperproliferation, genetic insta-
bility, and malignancy in cell culture and
murine models [4,5]. Normal cells sup-
press the effects of excess/stabilized cyclin
E via the G1/S checkpoint involving the
p53/p21 pathway.
Five isoforms of cyclin E, ranging in size
from 33 to 44 kDa, have been identified in
tumors over-expressing cyclin E. These
low molecular weight forms of cyclin E
(LMW-E) are generated through post-
translational cleavage of full-length cyclin
E by the elastase family of serine proteases
in tumor cells [6,7]. In comparison to full-
length cyclin E (50 kDa), LMW-E forms
are uniquely expressed in tumor cells,
exhibit enhanced CDK2-associated kinase
activity, have increased affinity for CDK2
[7–9], and exhibit decreased inhibition by
CDK2 inhibitors, p21 and p27 (Figure 1)
[10,11]. Ectopic expression of LMW-E
isoforms promotes cell proliferation, ge-
netic instability, centrosome amplification,
and malignancy [12,13]. In addition,
clinical studies have shown that high
LMW-E is strongly associated with poor
survival in breast cancer [2], colorectal
cancer [14,15], ovarian cancer [16], and
melanomas [17]. Given its unique prop-
erties and distinct function in human
cancers, targeting LMW-E could have
important therapeutic implications.
The study by Duong et al. in this issue
of PLoS Genetics [18] convincingly uncovers
the tumorigenic potential of LMW-E. The
authors used three different model sys-
tems—3D acinar cultures, xenograft trans-
plantation, and transgenic mice—to show
that overexpression of LMW-E is sufficient
to induce aberrant acinar morphogenesis
in culture and mammary tumors in mice
(Figure 1). When grown on Matrigel,
immortalized human mammary epithelial
cells (hMECs) expressing LMW-E exhibit
large misshapen multiacinar structures
resulting from defective growth arrest
and apoptosis that mimic morphologic
features of breast carcinomas. Further,
ectopic expression of LMW-E in immor-
talized hMECs promotes tumorigenesis in
xenografts and transgenic mice to a much
greater extent than full-length cyclin E.
Consistent with the reports by Akli et al.
and Nanos-Webb et al., tumorigenesis
associated with LMW-E is dependent on
CDK2 [19,20]. Furthermore, in vivo
passaging of tumor cells increases the
expression of LMW-E, suggesting that
LMW-E provides a selective growth ad-
vantage to the tumor. Duong et al. also
took advantage of a proteomic analysis
termed reverse-phase protein array assay
(RPPA) to examine protein expression
patterns in cultured tumor cells and in
breast tumors expressing high LMW-E
levels. Their analyses revealed that multi-
ple components of the b-RAF-ERK1/2-
mTOR pathway are elevated in these
cells. Activation of the b-RAF-ERK1/2-
mTOR pathway normally promotes cell
division and cell survival. Consistent with
this, the authors observed that endogenous
cyclin E levels are also increased in cells
expressing high LMW-E, indicative of the
existence of a positive feedback loop that
promotes cell proliferation. Both high
LMW-E levels and up-regulation of the
b-RAF-ERK1/2-mTOR signaling path-
way are associated with poor survival,
suggesting functional correlation of these
events in aggressive tumors. Importantly,
the authors demonstrated that combina-
tion therapy targeting LMW-E/CDK2
and the b-RAF-ERK1/2-mTOR pathway
has a synergistic effect in abrogating the
tumorigenic effect of LMW-E. Thus, the
identification of these downstream regula-
tors may provide novel biomarkers and/or
potential therapeutic targets for LMW-E–
expressing tumors.
The report that LMW-E potentiates
tumorigenesis in three independent model
systems associated with activation of the b-
RAF-ERK1/2-mTOR pathway is intrigu-
ing. However, there are many important
questions about the role of LMW-E in
tumorigenesis that need to be addressed. 1)
What is the functional relationship be-
tween LMW-E and full-length cyclin E? In
each tumor model reported by Duong et
al., the effect was examined by over-
expressing LMW-E in a background of
endogenous full-length cyclin E. Further,
the authors show that ectopic expression of
LMW-E in transplanted xenografts trig-
gers tumor evolution and results in
increased levels of endogenous cyclin E.
Thus, the contribution of endogenous full-
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excluded. In addition, Spruck et al.
reported that the level of LMW-E corre-
lates with full-length cyclin E, suggesting
that LMW-E reflects the total cyclin E
protein in primary breast tumors, cell
lines, and even normal breast tissue [21].
To examine the effect of LMW-E in the
absence of over-expression, and in the
absence of full-length cyclin E, it will be
important to use a knock-in model in
which expression of LMW-E is driven
from the endogenous cyclin E promoter. 2)
What is the relationship between LMW-E
and the b-Raf-ERK1/2-mTOR signaling
pathway? The authors demonstrated that
the b-Raf-ERK1/2-mTOR signaling
pathway is activated in tumors expressing
high levels of LMW-E. The b-Raf-ERK1/
2-mTOR pathway may be a downstream
signaling pathway deregulated by LMW-
E, or it could be a parallel survival
pathway selected in LMW-E–expressing
tumors. In particular, the fact that only
combinational therapy targeting both cy-
clin E–associated kinase activity and the b-
Raf-ERK1/2-mTOR pathway generates
an anti-tumor effect argues against a direct
cause–effect relationship and is suggestive
of a parallel pathway. 3) Is LMW-E
expression required for tumor growth
and does down-regulation of LMW-E alter
tumor growth, invasion, or metastasis?
The authors have generated an inducible
model that should facilitate these studies.
4) Is the tumor-promoting activity of
LMW-E due to enhanced deregulated
kinase activity or to alternative target
specificity? The LMW-E construct used
in these studies has an N-terminal deletion
(40 amino acids) that eliminates the
proposed nuclear localization signal
(NLS) and potentially affects the intracel-
lular localization and substrate specificity
[22,23]. 5) How is LMW-E generated in
tumors, and is it tumor-type specific? It
has been proposed and demonstrated by
Caruso et al. that many tumors have
elevated protease activity and decreased
levels of protease inhibitors such as elafin
[24] that may contribute to the generation
of LMW-E. Further characterization of
the proteolytic pathways that target cyclin
E in tumors may provide alternative
therapeutic targets.
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